MX2020006283A - Proceso para la preparación de opicapona y sus intermediarios. - Google Patents

Proceso para la preparación de opicapona y sus intermediarios.

Info

Publication number
MX2020006283A
MX2020006283A MX2020006283A MX2020006283A MX2020006283A MX 2020006283 A MX2020006283 A MX 2020006283A MX 2020006283 A MX2020006283 A MX 2020006283A MX 2020006283 A MX2020006283 A MX 2020006283A MX 2020006283 A MX2020006283 A MX 2020006283A
Authority
MX
Mexico
Prior art keywords
opicapone
preparation
intermediates
relates
present
Prior art date
Application number
MX2020006283A
Other languages
English (en)
Inventor
Arijit Das
Dhananjay G Sathe
Dnyaneshwar V Gawas
Sanjay Bhaskar Chowkekar
Ravindra Subhash Jagtap
Original Assignee
Unichem Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unichem Lab Ltd filed Critical Unichem Lab Ltd
Publication of MX2020006283A publication Critical patent/MX2020006283A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se refiere a un proceso para la preparación de opicapona y a un proceso para preparar intermediarios usados en el mismo.
MX2020006283A 2017-12-18 2018-12-04 Proceso para la preparación de opicapona y sus intermediarios. MX2020006283A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201721045330 2017-12-18
PCT/IB2018/059598 WO2019123066A1 (en) 2017-12-18 2018-12-04 Process for the preparation of opicapone and intermediates thereof

Publications (1)

Publication Number Publication Date
MX2020006283A true MX2020006283A (es) 2020-12-09

Family

ID=66993196

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006283A MX2020006283A (es) 2017-12-18 2018-12-04 Proceso para la preparación de opicapona y sus intermediarios.

Country Status (12)

Country Link
US (1) US20210087183A1 (es)
EP (1) EP3728241A4 (es)
JP (1) JP2021506762A (es)
KR (1) KR20200100075A (es)
CN (1) CN111511735A (es)
AU (1) AU2018392845A1 (es)
BR (1) BR112020011888A2 (es)
EA (1) EA202091259A1 (es)
MX (1) MX2020006283A (es)
PH (1) PH12020550871A1 (es)
WO (1) WO2019123066A1 (es)
ZA (1) ZA202003590B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112375014A (zh) * 2020-12-17 2021-02-19 重庆柳江医药科技有限公司 一种奥匹卡朋工艺杂质及制备方法和用途
US20240300930A1 (en) * 2021-02-26 2024-09-12 Msn Laboratories Private Limited, R&D Center Novel process for the preparation of 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide
CN116986980A (zh) * 2021-10-11 2023-11-03 常州锐博生物科技有限公司 一种香草酸的制备方法
CN114015332A (zh) * 2021-11-26 2022-02-08 广州双隆文化发展有限公司 一种马口铁印刷工艺
GB202204798D0 (en) * 2022-04-01 2022-05-18 Bial Portela & Ca Sa Prodrugs of opicapone
EP4727649A1 (en) * 2023-06-19 2026-04-22 Medichem, S.A. Process for preparing opicapone
CN120081837A (zh) * 2025-02-14 2025-06-03 江苏天士力帝益药业有限公司 一种低单杂高纯度的奥匹卡朋中间体05的制备方法
CN120490355B (zh) * 2025-07-14 2025-09-23 重庆锐恩医药有限公司 同时检测奥匹卡朋起始物料中三种有关物质的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006272978B2 (en) * 2005-07-26 2012-06-07 Bial - Portela & Ca, S.A. Nitrocatechol derivatives as COMT inhibitors
JP5864410B2 (ja) * 2009-04-01 2016-02-17 ノヴィファーマ ソシエテ アノニム ニトロカテコール誘導体を含む医薬製剤及びその製造方法
BR112014014341A2 (pt) * 2011-12-13 2017-08-22 Bial Portela & Ca Sa Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica

Also Published As

Publication number Publication date
US20210087183A1 (en) 2021-03-25
CN111511735A (zh) 2020-08-07
ZA202003590B (en) 2022-01-26
BR112020011888A2 (pt) 2020-11-24
JP2021506762A (ja) 2021-02-22
EA202091259A1 (ru) 2020-09-22
EP3728241A1 (en) 2020-10-28
AU2018392845A1 (en) 2020-06-18
PH12020550871A1 (en) 2021-04-05
EP3728241A4 (en) 2021-02-24
WO2019123066A1 (en) 2019-06-27
KR20200100075A (ko) 2020-08-25

Similar Documents

Publication Publication Date Title
PH12020550871A1 (en) Process for the preparation of opicapone and intermediates thereof
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
ZA201902141B (en) Acid-alpha glucosidase variants and uses thereof
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
PH12018500950B1 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
IN2014CH00247A (es)
ZA201902140B (en) Acid-alpha glucosidase variants and uses thereof
GEP20196974B (en) A novel crystalline form of a benzimidazole derivative and a preparation method thereof
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
TW201613893A (en) Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
IN2013MU00848A (es)
MX2017003301A (es) Producto refractario, relleno para fabricar el producto, procedimiento para fabricar el producto y uso del producto refractario.
MX2017015137A (es) Composicion farmaceutica oral de dosis diaria de isotretinoin.
IN2014CH00840A (es)
IN2015CH01182A (es)
SG10201908248PA (en) Processes for preparing fluoroketolides
MX2019010640A (es) Formas cristalinas de acido obeticolico.
GEP201706795B (en) Hexahydrofuropyrroles as pde1 inhibitors
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
MX383313B (es) Compuestos de quinolinilciclohexilpropanamida sustituidos y metodos mejorados para su preparacion
PH12017500499A1 (en) Synthesis of ent-progesterone and intermediates thereof
PH12018501166B1 (en) Concentrated gibberellin solution formulations
NZ721832A (en) Solid forms of tenofovir
MX2017008776A (es) Relleno para preparar un producto refractario, un procedimiento para preparar un producto refractario, un producto refractario, y uso de un producto refractario.